**Supplementary Figure Legends**

**Supplementary Figure 1:** Meta-analysis of the pooled HRs of OS for patients divided by p-S6K1 expression status, from Cox multivariate analyses (A).

**Supplementary Figure 2:** Meta-analysis of the pooled HRs of OS for esophageal squamous cell carcinoma (A), non-small cell lung cancer (B), nasopharyngeal carcinoma (C), breast cancer (D). **Supplementary Figure 3:** Meta-analysis of the pooled HRs of DFS (A), PFS (B) and RFS (C) for patients with abnormally expressed p-S6K1. **Supplementary Figure 4:** Meta-analysis of the pooled HRs of DFS (A), PFS (B) and RFS (C) for patients with abnormally expressed p-S6.
Supplementary Figure 1: Meta-analysis of the pooled HRs of OS for patients divided by p-S6K1 expression status, from Cox multivariate analyses.
**Supplementary Figure 2**: Meta-analysis of the pooled HRs of OS for esophageal squamous cell carcinoma (A), non-small cell lung cancer (B), nasopharyngeal carcinoma (C), breast cancer (D).
**Supplementary Figure 3:** Meta-analysis of the pooled HRs of DFS (A), PFS (B) and RFS (C) for patients with abnormally expressed p-S6K1.
Supplementary Figure 4: Meta-analysis of the pooled HRs of DFS (A), PFS (B) and RFS (C) for patients with abnormally expressed p-S6.